249 related articles for article (PubMed ID: 35801403)
1. Design and synthesis of thiazolidine-2,4-diones hybrids with 1,2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors:
Taghour MS; Elkady H; Eldehna WM; El-Deeb NM; Kenawy AM; Elkaeed EB; Alsfouk AA; Alesawy MS; Metwaly AM; Eissa IH
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1903-1917. PubMed ID: 35801403
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis, anti-proliferative evaluation, docking, and MD simulations studies of new thiazolidine-2,4-diones targeting VEGFR-2 and apoptosis pathway.
Taghour MS; Elkady H; Eldehna WM; El-Deeb N; Kenawy AM; Elkaeed EB; Alsfouk BA; Alesawy MS; Husein DZ; Metwaly AM; Eissa IH
PLoS One; 2022; 17(9):e0272362. PubMed ID: 36149902
[TBL] [Abstract][Full Text] [Related]
3. New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies.
Elkady H; Mahdy HA; Taghour MS; Dahab MA; Elwan A; Hagras M; Hussein MH; Ibrahim IM; Husein DZ; Elkaeed EB; Alsfouk AA; Metwaly AM; Eissa IH
Biochim Biophys Acta Gen Subj; 2024 Jun; 1868(6):130599. PubMed ID: 38521471
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, molecular docking, anticancer evaluations, and in silico pharmacokinetic studies of novel 5-[(4-chloro/2,4-dichloro)benzylidene]thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; El-Helby AA; Sakr H; Ayyad RR; Mahdy HA; Nasser M; Abulkhair HS; El-Hddad SSA
Arch Pharm (Weinheim); 2021 Feb; 354(2):e2000279. PubMed ID: 33073374
[TBL] [Abstract][Full Text] [Related]
5. Exploration of thiazolidine-2,4-diones as tyrosine kinase inhibitors: Design, synthesis, ADMET, docking, and antiproliferative evaluations.
Aziz NAAM; George RF; El-Adl K; Mahmoud WR
Arch Pharm (Weinheim); 2023 Mar; 356(3):e2200465. PubMed ID: 36403198
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
7. New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies.
Elkaeed EB; Taghour MS; Mahdy HA; Eldehna WM; El-Deeb NM; Kenawy AM; A Alsfouk B; Dahab MA; Metwaly AM; Eissa IH; El-Zahabi MA
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2191-2205. PubMed ID: 35975321
[TBL] [Abstract][Full Text] [Related]
8. New thiazolidine-2,4-diones as effective anti-proliferative and anti-VEGFR-2 agents: Design, synthesis, in vitro, docking, MD simulations, DFT, ADMET, and toxicity studies.
Elkady H; Abuelkhir AA; Rashed M; Taghour MS; Dahab MA; Mahdy HA; Elwan A; Al-Ghulikah HA; Elkaeed EB; Ibrahim IM; Husein DZ; Metwaly A; Eissa IH
Comput Biol Chem; 2023 Dec; 107():107958. PubMed ID: 37714080
[TBL] [Abstract][Full Text] [Related]
9. New benzothiazole hybrids as potential VEGFR-2 inhibitors: design, synthesis, anticancer evaluation, and
Al-Sanea MM; Hamdi A; Mohamed AAB; El-Shafey HW; Moustafa M; Elgazar AA; Eldehna WM; Ur Rahman H; Parambi DGT; Elbargisy RM; Selim S; Bukhari SNA; Magdy Hendawy O; Tawfik SS
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2166036. PubMed ID: 36691927
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and docking of novel thiazolidine-2,4-dione multitarget scaffold as new approach for cancer treatment.
Hanafy NS; Aziz NAAM; El-Hddad SSA; Abdelgawad MA; Ghoneim MM; Dawood AF; Mohamady S; El-Adl K; Ahmed S
Arch Pharm (Weinheim); 2023 Jul; 356(7):e2300137. PubMed ID: 37147779
[TBL] [Abstract][Full Text] [Related]
11. Novel benzothiazole-based dual VEGFR-2/EGFR inhibitors targeting breast and liver cancers: Synthesis, cytotoxic activity, QSAR and molecular docking studies.
Abd El-Meguid EA; Naglah AM; Moustafa GO; Awad HM; El Kerdawy AM
Bioorg Med Chem Lett; 2022 Feb; 58():128529. PubMed ID: 35007724
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, docking, ADMET profile, and anticancer evaluations of novel thiazolidine-2,4-dione derivatives as VEGFR-2 inhibitors.
El-Adl K; Sakr H; El-Hddad SSA; El-Helby AA; Nasser M; Abulkhair HS
Arch Pharm (Weinheim); 2021 Jul; 354(7):e2000491. PubMed ID: 33788290
[TBL] [Abstract][Full Text] [Related]
13. Discovery of new quinoline and isatine derivatives as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative, docking and MD simulation studies.
Taghour MS; Elkady H; Eldehna WM; El-Deeb N; Kenawy AM; Abd El-Wahab AE; Elkaeed EB; Alsfouk BA; Metwaly AM; Eissa IH
J Biomol Struct Dyn; 2023; 41(21):11535-11550. PubMed ID: 36617888
[TBL] [Abstract][Full Text] [Related]
14. New Series of VEGFR-2 Inhibitors and Apoptosis Enhancers: Design, Synthesis and Biological Evaluation.
Abdallah AE; Mabrouk RR; Elnagar MR; Farrag AM; Kalaba MH; Sharaf MH; El-Fakharany EM; Bakhotmah DA; Elkaeed EB; Al Ward MMS
Drug Des Devel Ther; 2022; 16():587-606. PubMed ID: 35281317
[TBL] [Abstract][Full Text] [Related]
15. Novel 2-indolinone thiazole hybrids as sunitinib analogues: Design, synthesis, and potent VEGFR-2 inhibition with potential anti-renal cancer activity.
Mahmoud HK; Farghaly TA; Abdulwahab HG; Al-Qurashi NT; Shaaban MR
Eur J Med Chem; 2020 Dec; 208():112752. PubMed ID: 32947227
[TBL] [Abstract][Full Text] [Related]
16. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
[TBL] [Abstract][Full Text] [Related]
17. Molecular Docking and In Vitro Anticancer Screening of Synthesized Arylthiazole linked 2H-indol-2-one Derivatives as VEGFR-2 Kinase Inhibitors.
Shalmali N; Bawa S; Ali MR; Kalra S; Kumar R; Zeya B; Rizvi MA; Partap S; Husain A
Anticancer Agents Med Chem; 2022; 22(11):2166-2180. PubMed ID: 34792005
[TBL] [Abstract][Full Text] [Related]
18. Design, synthesis, molecular docking, in silico ADMET profile and anticancer evaluations of sulfonamide endowed with hydrazone-coupled derivatives as VEGFR-2 inhibitors.
Sayed AM; Taher FA; Abdel-Samad MRK; El-Gaby MSA; El-Adl K; Saleh NM
Bioorg Chem; 2021 Mar; 108():104669. PubMed ID: 33515863
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and anticancer activity of novel 2-arylbenzimidazole/2-thiopyrimidines and 2-thioquinazolin-4(3H)-ones conjugates as targeted RAF and VEGFR-2 kinases inhibitors.
Ali IH; Abdel-Mohsen HT; Mounier MM; Abo-Elfadl MT; El Kerdawy AM; Ghannam IAY
Bioorg Chem; 2022 Sep; 126():105883. PubMed ID: 35636123
[TBL] [Abstract][Full Text] [Related]
20. Targeting the interplay between MMP-2, CA II and VEGFR-2 via new sulfonamide-tethered isomeric triazole hybrids; Microwave-assisted synthesis, computational studies and evaluation.
Reda Aouad M; Almehmadi MA; Faleh Albelwi F; Teleb M; Tageldin GN; Abu-Serie MM; Hagar M; Rezki N
Bioorg Chem; 2022 Jul; 124():105816. PubMed ID: 35489270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
